期刊文献+

高通量微型生物反应器在生物制药行业中的应用

Application of high-throughput miniature bioreactors in biopharmaceuticals
原文传递
导出
摘要 随着生物制药行业的快速发展,近年来高通量微型生物反应器系统得到较为广泛的应用。高通量微型生物反应器系统具有体积小、高通量、可放大性等优点,同时具有在线分析检测和过程反馈控制功能。目前,高通量微型生物反应器主要用于细胞株筛选、工艺优化及工艺表征等方面。其高通量结合实验设计开展实验研究,可大大缩短产品研发周期,提高工艺稳健性及产品质量可控性,加快研发项目进入临床及商业化的步伐。本文主要介绍了目前常见的几种高通量微型生物反应器系统,并以Ambr系统为例,介绍了高通量微型生物反应器系统在生物制药行业中的应用。 With the rapid development of biopharmaceutical industry, high-throughput miniature bioreactor systems have been widely used in recent years. The high-throughput miniature bioreactor system has the advantages of small size, high-throughput and good scalability, as well as the capability of on-line analysis and feedback control. At present, it is mainly applied in cell line selection, process optimization and process characterization. High-throughput technologies combining with experimental design can shorten the product development timelines significantly, improve the process robustness and product quality control, and accelerate the delivery of projects into clinical and commercial phase. This review mainly describes several common high-throughput miniature bioreactor systems and describes their applications in the biopharmaceutical industry, using Ambr system as an example.
作者 姚小员 裴新 查鑫华 张磊 季宇 YAO Xiao-yuan;PEI Xin;ZHA Xin-hua;ZHANG Lei;JI Yu(BIO Cell Culture Process Development Department,BeiGene(Suzhou)Co.,Ltd.,Suzhou 215123,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2021年第22期2075-2082,共8页 Chinese Journal of New Drugs
关键词 高通量微型生物反应器 Ambr系统 工艺开发 工艺表征 high-throughput miniature bioreactor Ambr system process development process characterization
  • 相关文献

参考文献2

二级参考文献20

  • 1Taubenberger J K, Morens D M. 1918 Influenza: The mother of all pandemics [J]. Emerging Infectious Diseases, 2006, 12(1): 15-22.
  • 2H7N9禽流感最新消息:广东15人死亡,全国死亡人数超百人[N/OL].国际财经时报,(2014-02-21)[2016-05-28].http://www.ibtimes.com.cn/articles/35575/20140221/28192.htm.
  • 3Crosse M. HHS has funded flexible manufacturing activities for medical countermeasures, but it is too soon to assess their effect [J]. Gao Reports, 2014, 35(3): 53-54.
  • 4The U.S. Department of Health and Human Services. Advanced development of recombinant influenza vaccine products and man- ufacturing capabilities for pandemic preparedness [R]. Washington DC: Department of Health and Human Services, 2009.
  • 5The U.S. Department of Health and Human Services. Fiscal year 2015 work plan (mid-year update) [R/OL]. 2015[2016-05-28]. oig.hhs.gov/reports-and-publications/archives/workplan/2015/ WP-Update-2015.pdf.
  • 6The Office of the Press Secretary of the White House. Fact sheet Middle class economics: The president' s fiscal year 2016 budget (investing in American innovation) [EB/OL]. (2015-02-02) [2016- 05-28]. Available from: http://gallery.mailchimp.com/6f332e- 973fea19c6d59ade453/files/White_House_Fact_Sheet_on_the_Budget.pdf.
  • 7Collins F S, Varmus H. A new initiative on precision medicine [J]. The New England Journal of Medicine, 2015, 372(9): 793 -795.
  • 8Herbert M. Revolutionising the manufacture of precision medi- cines [EB/OL]. (2015-06-23) [2016-05-28]. https://www.uk-cpi. com/news/revolutionising-manufacture-precision-medicines/.
  • 9Kaplan D. National science foundation (NSF) workshop report-- Advanced biomanufacturing [C/OL]. Virginia: NSF, 2013[2016- 05-28]. http://www.nsf.gov/eng/cbet/documents/adv_biomanufac- turing.pdf.
  • 10Ngibuini M. Automated mini bioreactor technology for microbial and mammalian cell culture: Flexible strategy to optimize early process development of biologics and vaccines [J]. Bioprocess International, 2014(9): 20-25.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部